-
1
ARDS phenotyping should reflect meaningful biology or physiology, guide specified decisions, and remain accessible across clinical and resource settings.
-
2
Biomarker panels can classify inflammatory ARDS phenotypes, but PHIND and SPARC showed implementation barriers involving recruitment, laboratory workflows, and incomplete classification.
-
3
Clinical classifiers infer inflammatory phenotypes from routinely collected data and may extend phenotyping beyond centers with specialized biomarker platforms.
-
4
Clinical classifiers require prospective validation because differences in practice, testing, and missing data may cause model drift across settings.
-
5
POLARIS will assess routine-data phenotypes for association with 28-day mortality, variation in early corticosteroid responses, and reproducibility across healthcare systems.
